HealthFortuneabout 1 hour ago
Rakuten Medical seeks 2028 FDA approval
3 min read
Japanese biotech firm Rakuten Medical is running Phase 3 clinical trials in the U.S. and aims for a 2028 FDA submission for its photoimmunotherapy technology. CEO Minami Maeda states the company is allocating 95% of resources to this goal, hoping to treat all solid tumors rather than just head and neck cancers.
Level
Hype check
Tap to vote and see what everyone thinks.
